What are the best treatments for early chronic kidney disease? A background paper prepared for the UK consensus conference on early chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 22, Issue SUPPL.9, 2007, Pages

  Saweirs, Walaa W M ^a   Goddard, Jane ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; EXERCISE; HUMAN; LIFESTYLE; PATHOPHYSIOLOGY; REVIEW;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; EXERCISE; HUMANS; KIDNEY FAILURE, CHRONIC; LIFE STYLE;

EID: 41149155023     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm447     Document Type: Conference Paper

References (81)

1. Levey AS, Eckardt K-U, Tsukamoto Y et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100
2. Buckalew VM, Berg RL, Wang S-R et al. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Am J Kidney Dis 1996; 28: 811-821
3. Coresh J, Wei GL, McQuillan G et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third national health and nutrition examination survey (1988-1994). Arch Intern Med 2001; 161: 1207-1216
4. Maki DD, Ma JZ, Louis TA et al. Long-Term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155: 1073-1080
5. Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin-Angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-Analysis. Lancet 2005; 366: 2026-2033
6. Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-Analysis. Ann Intern Med 2003; 139: 244-252
7. He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease. Overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 1999; 138: S211-S219
8. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713
9. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. the modification of diet in renal disease study. Ann Intern Med 1995; 123: 754-762
10. Kidney Disease Outcome Quality Initiative. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-S290
11. Joint Speciality Committee on Renal Medicine of the Royal College of Physicians and the Renal Association atRCoGP. Chronic Kidney Disease in adults: UK guidelines for identification, management and referral. Royal College of Physicians, London: 2006
12. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560-2571
13. Williams B, Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 (BHS IV). J Hum Hypertens 2004; 18: 139-185
14. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266
15. Zeeuw DD, Remuzzi G, Parving H-H et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320
16. Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254-2261
17. Lea J, Greene T, Hebert L et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease. results of the african american study of kidney disease and hypertension. Arch Intern Med 2005; 165: 947-953
18. Atkins RC, Polkinghorne KR, Briganti EM et al. Prevalence of albuminuria in Australia: The AusDiab Kidney Study. Kidney Int 2004; 66: S22
19. Donadio JV, Bergstralh EJ, Grande JP et al. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant 2002; 17: 1197-1203
20. Jafar T, Stark P, Schmid C et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60: 1131-1140
21. Atkins R, Briganti E, Lewis J et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281-287
22. Strippoli GL, Craig M, Craig J. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2005; 4: CD004136
23. Jafar TH, Stark PC, Schmid CH et al. The effect of angiotensinconverting- enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 2005; 67: 265-271
24. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-Analysis of individual patient data. Ann Intern Med 2001; 134: 370-379
25. Strippoli GFM, Craig M, Deeks JJ et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. Br Med J 2004; 329: 828-839
26. Kshirsagar AV, Joy MS, Hogan SL et al. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000; 35: 695-707
27. Hamilton R, Kane M, Demers J. Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: A metaanalysis. Pharmacotherapy 2003; 23: 909-915
28. Lovell H. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. Cochrane Database Syst Rev 1999; 3
29. Doulton TWR, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005; 45: 880-886
30. MacKinnon M, Shurraw S, Akbari A et al. Combination therapy with an angiotensin receptor blocker and an ace inhibitor in proteinuric renal disease. A systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48: 8-20
31. Bakris G, Weir M, Secic M et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65: 1991-2002
32. Marre M, Puig J, Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004; 22: 1613-1622
33. Molyneaux L, Willey K, Yue D. Indapamide is as effective as captopril in the control of microalbuminuria in diabetes. J Cardiovasc Pharmacol 1996; 27: 424-427
34. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease. A meta-Analysis of randomized trials. Ann Intern Med 1997; 127: 337-345
35. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329: 977-986
36. United Kingdom Prospective Diabetes Study (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
37. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117
38. British Cardiac Society BHS, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91: v1-v52
39. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: A meta-Analysis. Kidney Int 2001; 59: 260-269
40. Maisch NM, Pezzillo KK. HMG-CoA reductase inhibitors for the prevention of nephropathy. Ann Pharmacother 2004; 38: 342-345
41. Tonelli M, Isles C, Craven T et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005; 112: 171-178
42. Diercks GFH, Janssen WMT, van Boven AJ et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the prevention of REnal and vascular ENdstage disease intervention trial [PREVEND IT]). Am J Cardiol 2000; 86: 635-638
43. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int 2003; 84: S207-S210
44. Stengel B, Tarver-Carr M, Powe N et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003; 14: 479-487
45. Chase HP, Garg SK, Marshall G et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 1991; 265: 614-617
46. Halimi J, Giraudeau B, Vol S et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int 2000; 58: 1285-1292
47. Regalado M, Yang S, Wesson D. Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis 2000; 35: 767-769
48. Orth SR, Stockmann A, Conradt C et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998; 54: 926-931
49. Orth S. Smoking - a renal risk factor. Nephron 2000; 86: 12
50. Taal M, Brenner B. Evolving strategies for renoprotection: nondiabetic chronic renal disease. Curr Opin Nephrol Hypertens 2001; 10: 523-531
51. Shankar A, Klein R, Klein BEK. The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol 2006; 164: 263-271
52. Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877-884
53. Hansen HP, Tauber-Lassen E, Jensen BR et al. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002; 62: 220-228
54. Meloni C, Morosetti M, Suraci C et al. Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks? J Ren Nutr 2002; 12: 96-101
55. Pijls LT, de Vries H, van Eijk JT et al. Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: A randomized trial. Eur J Clin Nutr 2002; 56: 1200-1207
56. Meloni C, Tatangelo P, Cipriani S et al. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure. J Ren Nutr 2004; 14: 208-213
57. Sacks FM, Svetkey LP, Vollmer WM et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 2001; 344: 3-10
58. Hooper L, Bartlett C, Davey Smith G et al. Systematic review of long term effects of advice to reduce dietary salt in adults. Br Med J 2002; 325: 628-636
59. Chagnac A, Weinstein T, Herman M et al. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003; 14: 1480-1486
60. Morales E, Valero M, León M et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41: 319-327
61. Pechter U, Maaroos J, Mesikepp S et al. Regular low-intensity aquatic exercise improves cardio-respiratory functional capacity and reduces proteinuria in chronic renal failure patients. Nephrol Dial Transplant 2003; 18: 624-625
62. Fisher J. Mechanism of the anemia of chronic renal failure. Nephron 1980; 25: 106-111
63. Astor BC, Muntner P, Levin A et al. Association of Kidney Function With Anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162: 1401-1408
64. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335
65. Xue JL, St Peter WL, Ebben JP et al. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002; 40: 1153-1161
66. Rao M, Pereira B. Prospective trials on anemia of chronic disease: the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Kidney Int 2003; 87 [suppl]: S12-S19
67. Eckardt K-U. The CREATE trial-building the evidence. Nephrol Dial Transplant 2001; 16: 16-18
68. Cody J, Daly C, Campbell M et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005
69. Locatelli F, Aljama P, Barany P et al. Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 2004; 19: ii1-ii47
70. Kraut J, Kurtz I. Metabolic Acidosis of CKD: diagnosis, clinical characteristics, and treatment. Am J Kidney Dis 2005; 45: 978-993
71. Kopple JD, Kalantar-Zadeh K, Mehrotra R. Risks of chronic metabolic acidosis in patients with chronic kidney disease. Kidney Int 2005; 67: S21-S27
72. Bailey JL. Metabolic acidosis: An unrecognized cause of morbidity in the patient with chronic kidney disease. Kidney Int 2005; 68: S15-S23
73. Goodman W, London G, Amann K et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004; 43: 572-579
74. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: 1-201
75. Levey A, Beto J, Coronado B et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853-906
76. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the american heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003; 108: 2154-2169
77. Mann JFE, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636
78. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. The Lancet 2005; 366: 895-906
79. Tokmakova MP, Skali H, Kenchaiah S et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) Study. Circulation 2004; 110: 3667-3673
80. Ruilope LM, Salvetti A, Jamerson K et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218-225
81. Sever P, Dahlof B, Poulter N et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-Than-Average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Drugs 2004; 64: 43-60